United States-based Amgen (NASDAQ:AMGN) announced on Tuesday that it has reported its financial results for the second quarter of 2021.
The company reported an increase in total revenue by 5% to USD6.5bn in the second quarter of 2021 compared to USD6.2bn the year-ago period. A decrease in GAAP earnings per share by 73% to USD0.81 in the second quarter of 2021 compared to ISD3.05 in the year-ago period.
It posted a decrease in GAAP operating income by 64% to USD0.8bn and a decrease in GAAP operating margin by 25.8 percentage points to 13.5%.
It reported Non-GAAP EPS at USD4.38 in the second quarter of 2021, up 4% compared to USD4.20 in the year-ago period.
'We achieved solid, volume-driven growth in the quarter as our business recovered from the effects of the pandemic,' said Robert A Bradway, chairman and chief executive officer. 'As we look to the balance of the year, we are excited to be launching LUMAKRAS, a first-in-class lung cancer treatment, and advancing a robust pipeline of potential new medicines to meet the demands of patients around the world.'
Danaher Corporation announces quarterly cash dividend
Abbott announces quarterly common dividend
Bruker expands Preclinical Imaging Portfolio with acquisition of Spectral Instruments Imaging
Fusion Antibodies announces receipt of follow-on project and provides R&D update
Alvotech reports positive results for AVT03, potential biosimilar to Prolia and Xgeva